```html

Upper Limb Deep Vein Thrombosis (DVT)

What is Upper Limb DVT?

Deep vein thrombosis (DVT) is the formation of a blood clot (thrombus) within a deep vein. While most DVTs occur in the legs, upper‑limb DVT refers to clots that develop in the veins of the arm, shoulder, or neck (subclavian, axillary, brachial, or internal jugular veins). The clot can partially or completely block blood flow, leading to swelling, pain, and, in rare cases, a life‑threatening pulmonary embolism (PE) if the clot dislodges and travels to the lungs.

Upper‑limb DVT accounts for about 4–10 % of all DVT cases, but its incidence is rising because of increased use of central venous catheters, pacemakers, and intensive‑care interventions.<sup>1</sup> Early recognition is essential because symptoms can be subtle, and delayed treatment increases the risk of complications such as post‑thrombotic syndrome, recurrent clotting, and PE.

Common Causes

Several conditions predispose an individual to clot formation in the upper extremity. The most frequent triggers are listed below:

• Central venous catheters (CVCs) or peripherally inserted central catheters (PICCs) – mechanical irritation and endothelial injury.
• Implanted cardiac devices (pacemakers, implantable cardioverter‑defibrillators) – leads traverse the subclavian vein.
• Prolonged immobilisation – especially after shoulder surgery, casting, or ICU stay.
• Thoracic outlet syndrome (TOS) – repetitive compression of the subclavian vein between the first rib and clavicle.
• Trauma or fracture of the clavicle, humerus, or scapula causing venous injury.
• Malignancy – especially lung, breast, or hematologic cancers that increase hypercoagulability.
• Hormonal therapy – oral contraceptives, hormone replacement, or anabolic steroids.
• Inherited or acquired thrombophilia – Factor V Leiden, prothrombin G20210A mutation, antiphospholipid antibody syndrome.
• Obesity and sedentary lifestyle – contribute to systemic hypercoagulability.
• Infection or inflammation – cellulitis, catheter‑related sepsis, or autoimmune vasculitis.

Associated Symptoms

Symptoms may develop gradually over days or appear abruptly. Commonly reported signs include:

• Swelling of the affected arm, hand, or forearm – often asymmetric compared with the opposite side.
• Pain, tenderness, or a heaviness sensation that worsens with arm elevation or use.
• Visible superficial veins (collateral circulation) due to rerouting of blood.
• Redness or a bluish discoloration of the skin (cyanosis).
• Feeling of tightness or “fullness” in the chest/neck if the subclavian or internal jugular vein is involved.
• Occasional low‑grade fever (especially with catheter‑related infection).
• Rarely, shortness of breath, chest pain, or rapid heart rate if a clot breaks off and causes a pulmonary embolism.

When to See a Doctor

Because upper‑limb DVT can mimic other conditions (muscle strain, infection, lymphedema), a low threshold for medical evaluation is advised. Seek care promptly if you notice any of the following:

• Sudden or progressive swelling of one arm that does not resolve with rest.
• Persistent pain or tenderness that worsens with arm movement.
• Visible purple or red streaks on the skin (possible sign of clot migration).
• Feeling of tightness in the neck or chest accompanied by shortness of breath.
• Fever >38 °C (100.4 °F) together with swelling – suggests infection plus clot.
• History of a recent central line, pacemaker insertion, major surgery, or cancer treatment.

Diagnosis

Evaluation combines a careful clinical assessment with imaging studies. The typical diagnostic pathway includes:

1. Clinical risk assessment

• Use of scoring systems (e.g., modified Wells criteria for upper‑extremity DVT) to estimate pre‑test probability.
• Review of personal and family clotting history, recent procedures, and medication use.

2. Laboratory tests

• D-dimer – a breakdown product of fibrin; a normal result can effectively rule out DVT in low‑risk patients, but it is nonspecific and often elevated after surgery or infection.
• Complete blood count, metabolic panel, and coagulation profile to identify anemia, infection, or underlying clotting disorders.

3. Imaging

• Duplex ultrasonography – first‑line, non‑invasive test. It visualises vein compressibility, flow patterns, and clot location.
• Contrast‑enhanced CT or MR venography – reserved for inconclusive ultrasound or when central veins (e.g., subclavian, brachiocephalic) are suspected.
• Venography – gold standard but rarely performed because of its invasiveness; used mainly when interventional therapy is planned.

4. Additional evaluations (if indicated)

• Thrombophilia panel (genetic and antiphospholipid antibodies) for recurrent or unprovoked clots.
• Chest X‑ray or CT pulmonary angiography if PE is suspected.

Treatment Options

Therapy aims to prevent clot propagation, reduce the risk of PE, alleviate symptoms, and preserve arm function. Management combines anticoagulation, mechanical measures, and, when necessary, invasive procedures.

Anticoagulation (first‑line)

• Low‑molecular‑weight heparin (LMWH) (e.g., enoxaparin) – given subcutaneously for 5‑7 days, often used as a bridge to oral agents.
• Direct oral anticoagulants (DOACs) – apixaban, rivaroxaban, or edoxaban are now preferred for most patients because they do not require routine monitoring and have comparable safety to warfarin.<sup>2</sup>
• Warfarin – an option when DOACs are contraindicated (e.g., severe renal impairment, pregnancy). Requires INR monitoring (target 2.0‑3.0).
• Typical treatment duration: 3 months for provoked clots (e.g., catheter‑related) and 6‑12 months or indefinite for unprovoked or recurrent events.<sup>3</sup>

Catheter‑directed therapies

• Thrombolysis – catheter‑delivered tissue plasminogen activator (tPA) for extensive, symptomatic clots, especially in young, active patients.
• Pharmacomechanical thrombectomy – combines low‑dose thrombolytics with mechanical clot disruption; reduces bleeding risk.
• Venous stenting or angioplasty – indicated when an anatomic obstruction (e.g., thoracic outlet syndrome) remains after clot resolution.

Supportive measures

• Elevation of the affected arm and use of a compression sleeve (if tolerated) to decrease swelling.
• Analgesics such as acetaminophen or short‑course NSAIDs for pain relief.
• Physical therapy after the acute phase to restore range of motion and prevent stiffness.
• Prompt removal of unnecessary central lines or catheters; replace with the smallest gauge possible.

When to consider surgery

Rarely required, but thoracic outlet decompression surgery (first rib resection) may be indicated for recurrent clots caused by anatomical compression that does not improve with anticoagulation alone.

Prevention Tips

Many risk factors are modifiable. Incorporate the following strategies whenever possible:

• Minimise indwelling catheter time – use the smallest catheter needed and remove it promptly when no longer essential.
• Maintain active movement – gentle shoulder and arm exercises during prolonged bed rest or after surgery.
• Stay hydrated – adequate fluid intake reduces blood viscosity.
• Weight management – BMI < 30 kg/m² lowers overall clot risk.
• Smoking cessation – eliminates a major pro‑thrombotic factor.
• Review medications – discuss risks of hormone therapy or steroids with your physician.
• Screen for thrombophilia if you have a personal or family history of unexplained clots.
• Use compression garments if you have chronic venous insufficiency or a history of upper‑limb DVT.
• Post‑operative protocols – follow surgeon’s instructions for early mobilization after shoulder or neck surgery.

Emergency Warning Signs

Key Take‑aways

Upper‑limb DVT, though less common than leg DVT, is a serious condition that requires timely diagnosis and treatment. Awareness of risk factors—especially central lines, cardiac devices, and thoracic outlet compression—helps patients and clinicians catch the problem early. Anticoagulation remains the cornerstone of therapy, while catheter‑directed interventions are reserved for extensive or refractory clots. Preventive measures, such as limiting catheter duration and staying active, can markedly lower the chance of recurrence.

For personalized advice, always discuss your symptoms, medical history, and treatment options with a qualified healthcare professional.

---

References:
1. Kearon C, et al. “Upper‑extremity deep vein thrombosis.” Thrombosis Research. 2022.
2. American College of Chest Physicians (ACCP) Guidelines for Antithrombotic Therapy. 2021.
3. National Institutes of Health (NIH) – “Management of Venous Thromboembolism.” 2023.
4. Mayo Clinic. “Deep vein thrombosis (DVT) – Symptoms & causes.” Updated 2024.
5. CDC. “Guidelines for Prevention of Venous Thromboembolism.” 2022. ```